Literature DB >> 1151963

Biotransformation of phenprocoumon in the rat.

L R Pohl, R E Haddock, W F Trager.   

Abstract

The metabolic fate of phenprocoumon [3-(alpha-ethylbenzyl)-4-hydroxycoumarin] in the rat is described. The major metabolites, 4',-6-,7-, and 8-hyproxyphenprocoumon, have been identified yb mass spectrometry, TLC, and uv and compared with authentic smaples. Metabolites are mainly excreted via the feces. The results are compared with those previously reported for warfarin.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1151963

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  7 in total

Review 1.  Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol.

Authors:  Mike Ufer
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

2.  Biliary excretion of phenprocoumon and metabolites.

Authors:  J X de Vries; R Raedsch; U Völker; I Walter-Sack; E Weber
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

3.  Effect of serum protein binding on pharmacokinetics and anticoagulant activity of phenprocoumon in rats.

Authors:  D Trenk; E Jähnchen
Journal:  J Pharmacokinet Biopharm       Date:  1980-04

4.  Lack of effect of cimetidine on action of phenprocoumon.

Authors:  J Harenberg; R Zimmermann; C Staiger; J X de Vries; E Walter; E Weber
Journal:  Eur J Clin Pharmacol       Date:  1982-10       Impact factor: 2.953

Review 5.  Pharmacogenetics of oral anticoagulants: a basis for dose individualization.

Authors:  Simone Stehle; Julia Kirchheiner; Andreas Lazar; Uwe Fuhr
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

6.  Interaction of phenylbutazone with racemic phenprocoumon and its enantiomers in rats.

Authors:  W Schmidt; E Jähnchen
Journal:  J Pharmacokinet Biopharm       Date:  1979-12

7.  Phenprocoumon metabolites in human plasma; characterization by HPLC and GC-MS.

Authors:  J X de Vries; R Zimmermann; J Harenberg
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.